

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * NEIS JOHN		2. Date of Event Requiring Statement (Month/Day/Year) 08/14/2014	3. Issuer Name and Ticker or Trading Symbol Collectar Biosciences, Inc. [CLRB]	
(Last) (First) (Middle) C/O COLLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE	(Street) MADISON, WI 53716		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
(City) (State) (Zip)	5. If Amendment, Date Original Filed (Month/Day/Year)			
6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(2)	12/13/2023	Common Stock	2,500	\$ 7.4	D	
Stock Option (right to buy)	(2)	12/14/2022	Common Stock	2,500	\$ 15	D	
Stock Option (right to buy)	(2)	12/16/2021	Common Stock	2,500	\$ 9	D	
Stock Option (right to buy)	(2)	05/18/2021	Common Stock	5,000	\$ 28	D	
Convertible Debenture (right to buy)	02/06/2014	02/06/2016	Common Stock	50,000	\$ 10	I	See Foonote (1) (3)
Stock Purchase Warrant (right to buy)	02/20/2013	02/20/2015	Common Stock	2,750	\$ 10	I	See Foonote (1)
Stock Purchase Warrant (right to buy)	06/13/2012	06/13/2017	Common Stock	13,500	\$ 25	I	See Foonote (1)
Stock Purchase Warrant (right to buy)	04/08/2011	03/31/2016	Common Stock	55,000	\$ 15	I	See Foonote (1)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
NEIS JOHN C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON, WI 53716	X			

Signatures

/s/ Paul Bork, attorney-in-fact for John Neis		08/14/2014
<small>**Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These securities are held by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership. VIESF IV GP LLC is the general partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership.

(1) The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by seven managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

(2) Option vests in equal quarterly increments over a period of two years from the date of grant. Option expires on the tenth anniversary of the date of grant.

(3) In connection with the issuance of the convertible debentures, Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership were also granted a warrant to purchase 50,000 shares of common stock at an exercise price of \$20.00 per share. The warrants become exercisable only upon the conversion of the convertible debentures and expire February 6, 2019.

Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Collectar Biosciences, Inc. The authority of Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Collectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Collectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated: August 13, 2014

Signed: /s/ John Neis

Print Name: John Neis
